Evidence map›Paper›PMID 34302589›Full record

Trial reportBreast cancer research and treatment2021

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Sara M Balch, Ines Vaz-Luis, Tianyu Li, Nabihah Tayob, Esha Jain, Karla Helvie, Jorge E Buendia-Buendia, Erin Shannon, Steven J Isakoff, Nadine M Tung and 4 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01912963 (A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01912963 phase2terminatednot on this map

A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2013 to 2016Enrolled32ConditionsHER2-positive Breast Cancer, Metastatic Breast CancerArmsPertuzumab, Trastuzumab, eribulin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. An Insight into Molecular Targets of Breast Cancer Brain Metastasis.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Sara M BalchThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ines Vaz-LuisDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.
Tianyu LiDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Nabihah TayobDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Esha JainThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Karla HelvieDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.
Jorge E Buendia-BuendiaThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Erin ShannonThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven J IsakoffMassachusetts General Hospital, Boston, MA, USA.
Nadine M TungHarvard Medical School, Boston, MA, USA.
Ian E KropDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA.
Nikhil Wagle *The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Rachel A Freedman *Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1259, Boston, MA, 02215, USA. rafreedman@partners.org.ORCID http://orcid.org/0000-0003-0460-674X
Broad Institute · USHarvard University · USDana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USInserm · FR

Funding

American Cancer Society MRSG-14-240-01-CPPBSusan G. Komen CCR14298143Susan G. Komen CCRCR18552788
6 · The paper itself

Abstract

purposeThere are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response.

methodsAfter a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m

resultsThe six-patient run-in established a dose of eribulin 1.4 mg/m

conclusionEribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape.

trial registrationwww.clinicaltrials.gov , NCT01912963. Registered 24 July 2013.

Indexed as

Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleFuransGenomicsHumansKetonesPolyether PolyketidesTrastuzumabTreatment OutcomeAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonespertuzumabPolyether PolyketidesTrastuzumabEribulin mesylateHER2+ breast cancerPertuzumabTrastuzumab

Identifiers

PMID34302589
OpenAlexW3185165987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.